Clinical trial

A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes

Recruiting now · Phase 2 · 9 countries · Registry ID NCT07415954

Recruiting nowPhase 2Interventional

What this study is about

This study is being done to look at the effect and safety of different doses of NNC0662-0419 in people living with type 2 diabetes when compared to placebo or semaglutide. The purpose of this clinical study is to find out if NNC0662-0419 is effective and safe for treating people living with type 2 diabetes. Participants will get either NNC0662-0419, semaglutide or placebo. Which treatment participants get is decided by chance. NNC0662-0419 is a new medicine which cannot be prescribed by doctors but has previously been tested in humans. Semaglutide is an approved medication to treat type 2 diabetes.

A promising-looking record is not the same as confirmed eligibility. The study team must review the full criteria and current recruitment status.

Basic eligibility

Age18 Years to 75 Years

SexAll

Healthy volunteersNot accepted

ConditionDiabetes Mellitus, Type 2

Full registry criteria

Inclusion criteria * Male or female (sex at birth). * Age 18-75 years (both inclusive) at the time of signing the informed consent. * Glycated haemoglobin (HbA1c) of 7.0-10.0 percent (%) (53-86 millimoles per mole \[mmol/mol\]) (both inclusive) as assessed by central laboratory at screening. * Willingness to obtain a high weight loss (greater than \[\>\] 25% of weight at baseline). Exclusion criteria * Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within 90 days before screening. However, short term insulin treatment for a maximum of 14 consecutive days and prior insulin treatment for gestational diabetes are allowed. * Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination. * Known hypoglycaemic unawareness as indicated by the investigator according to Clarke's Questionnaire.

Treatments and study arms

NNC0662-0419

Drug

NNC0662-0419 will be administered subcutaneously.

Semaglutide

Drug

Semaglutide will be administered subcutaneously.

Placebo

Drug

Placebo will be administered subcutaneously.

Primary outcomes

Change in glycated haemoglobin (HbA1c) (week 16)From baseline (week 0) to week 16

Measured as percentage-point (%-point).

Change in HbA1c (week 28)From baseline (week 0) to week 28

Measured as %-point.

Change in HbA1c (week 40)From baseline (week 0) to week 40

Measured as %-point.

Study locations

63 locations were listed when this page was built. The first 40 are shown.

Opca bolnica Karlovac🌐 Karlovac, Croatia